2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Ulf Landmesser; M. John Chapman; Jane K. Stock; Pierre Amarenco; Jill J. F. Belch; Jan Borén; Michel Farnier; Brian A. Ference; Stephan Gielen; Ian Graham; Diederick E. Grobbee; G. Kees Hovingh; Thomas F. Luscher; Massimo F. Piepoli; Kausik K. Ray; Erik S. Stroes; Olov Wiklund; Stephan Windecker; Jose Luis Zamorano; Fausto Pinto; Lale Tokgozoglu; Jeroen J. Bax; Alberico L. Catapano

doi:10.1093/eurheartj/ehx549

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Ulf Landmesser (Lead / Corresponding author), M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J. F. Belch, Jan Borén, Michel Farnier, Brian A. Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Luscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto PintoLale Tokgozoglu, Jeroen J. Bax, Alberico L. Catapano

Molecular and Clinical Medicine

Research output: Contribution to journal › Comment/debate › peer-review

175 Citations (Scopus)

133 Downloads (Pure)

Abstract

The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

Original language	English
Pages (from-to)	1131-1143
Number of pages	13
Journal	European Heart Journal
Volume	39
Issue number	14
Early online date	16 Oct 2017
DOIs	https://doi.org/10.1093/eurheartj/ehx549
Publication status	Published - 7 Apr 2018

Keywords

atherosclerosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurheartj/ehx549

Author Accepted Manuscript
This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal following peer review. The version of record '2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in patients with ASCVD or in familial hypercholesterolaemia', European Heart Journal (2017) is available online at: https://doi.org/10.1093/eurheartj/ehx549.
Accepted author manuscript, 448 KB

Fingerprint

Dive into the research topics of '2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia'. Together they form a unique fingerprint.

175 Citations
1 Article

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L., Pinto, F., & 3 othersTokgozoglu, L., Bax, J. J. & Catapano, A. L., 24 Nov 2017, In: European Heart Journal. p. 1-1 1 p., ehx648.
Research output: Contribution to journal › Article › peer-review

Open Access

2 Citations (Scopus)

Cite this

Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M. F., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L., ... Catapano, A. L. (2018). 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal, 39(14), 1131-1143. Advance online publication. https://doi.org/10.1093/eurheartj/ehx549

@article{4da4a4829a2546f6b416312ca71f5f56,

title = "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia",

abstract = "The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.",

keywords = "atherosclerosis",

author = "Ulf Landmesser and Chapman, {M. John} and Stock, {Jane K.} and Pierre Amarenco and Belch, {Jill J. F.} and Jan Bor{\'e}n and Michel Farnier and Ference, {Brian A.} and Stephan Gielen and Ian Graham and Grobbee, {Diederick E.} and Hovingh, {G. Kees} and Luscher, {Thomas F.} and Piepoli, {Massimo F.} and Ray, {Kausik K.} and Stroes, {Erik S.} and Olov Wiklund and Stephan Windecker and Zamorano, {Jose Luis} and Fausto Pinto and Lale Tokgozoglu and Bax, {Jeroen J.} and Catapano, {Alberico L.}",

year = "2018",

month = apr,

day = "7",

doi = "10.1093/eurheartj/ehx549",

language = "English",

volume = "39",

pages = "1131--1143",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "14",

}

Landmesser, U, Chapman, MJ, Stock, JK, Amarenco, P, Belch, JJF, Borén, J, Farnier, M, Ference, BA, Gielen, S, Graham, I, Grobbee, DE, Hovingh, GK, Luscher, TF, Piepoli, MF, Ray, KK, Stroes, ES, Wiklund, O, Windecker, S, Zamorano, JL, Pinto, F, Tokgozoglu, L, Bax, JJ & Catapano, AL 2018, '2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia', European Heart Journal, vol. 39, no. 14, pp. 1131-1143. https://doi.org/10.1093/eurheartj/ehx549

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. / Landmesser, Ulf (Lead / Corresponding author); Chapman, M. John; Stock, Jane K. et al.
In: European Heart Journal, Vol. 39, No. 14, 07.04.2018, p. 1131-1143.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

AU - Landmesser, Ulf

AU - Chapman, M. John

AU - Stock, Jane K.

AU - Amarenco, Pierre

AU - Belch, Jill J. F.

AU - Borén, Jan

AU - Farnier, Michel

AU - Ference, Brian A.

AU - Gielen, Stephan

AU - Graham, Ian

AU - Grobbee, Diederick E.

AU - Hovingh, G. Kees

AU - Luscher, Thomas F.

AU - Piepoli, Massimo F.

AU - Ray, Kausik K.

AU - Stroes, Erik S.

AU - Wiklund, Olov

AU - Windecker, Stephan

AU - Zamorano, Jose Luis

AU - Pinto, Fausto

AU - Tokgozoglu, Lale

AU - Bax, Jeroen J.

AU - Catapano, Alberico L.

PY - 2018/4/7

Y1 - 2018/4/7

N2 - The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

AB - The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

KW - atherosclerosis

U2 - 10.1093/eurheartj/ehx549

DO - 10.1093/eurheartj/ehx549

M3 - Comment/debate

C2 - 29045644

SN - 0195-668X

VL - 39

SP - 1131

EP - 1143

JO - European Heart Journal

JF - European Heart Journal

IS - 14

ER -

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal. 2018 Apr 7;39(14):1131-1143. Epub 2017 Oct 16. doi: 10.1093/eurheartj/ehx549

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Research output

Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)

Cite this